People · Operator
Named in public records as an officer, director or promoter · active 2018–2022 · Other, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Certified Collision Group Holdings, LLC | — | Other | Series C | $44.0M | $519.9M | 2022 |
| Celixir plc | — | Biotechnology | Seed | $1.5M | $66.6M | 2018 |
Martin Evans at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Martin Evans on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Chaim Hurvitz | 1 | 6 |
| Thomas Ritchie | 1 | 5 |
| Evan Weinstein | 1 | 4 |
| Nic Meiring | 1 | 3 |
| Conor Kehoe | 1 | 1 |
| Gary Pisano | 1 | 1 |
| A Reginald | 1 | 1 |
| Mubasher Sheikh | 1 | 1 |
| Sabena Sultan | 1 | 1 |
| David Preston | 1 | 1 |
| Lee Chapman | 1 | 1 |
| Duncan Ribbons | 1 | 1 |
| Darrin Disley | 1 | 1 |
| Nigel Scott | 1 | 1 |
| Marc Sebastian | 1 | 1 |
| Christopher Chase | 1 | 1 |
| Fiona Murray | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.